Ronald A. Primas,MD,FACP,FACPM

10.3K posts

Ronald A. Primas,MD,FACP,FACPM banner
Ronald A. Primas,MD,FACP,FACPM

Ronald A. Primas,MD,FACP,FACPM

@Primas

Integrative board certified internist/concierge #doctor available 24/7 for housecalls, preventive, urgent & routine care, #longevity,#healthspan #Biohacker.Dad.

New York Entrou em Mart 2009
2.9K Seguindo6.7K Seguidores
Ronald A. Primas,MD,FACP,FACPM retweetou
Andrew Steele
Andrew Steele@statto·
When this idea stops being an aside in a semi-related piece that’s so obvious it doesn’t need fact-checking, we will be getting somewhere! (No shade on @Noahpinion in particular, this is a very common and appealing trope!) It matters because… x.com/statto/status/…
Andrew Steele@statto

@Noahpinion Side note, but this isn’t true! Longevity biotech is maybe a few percent of overall biotech. It’s received maybe $10B in total ever, which is vastly less than modern billionaire net worth. If anything, it’s striking how *little* the rich and powerful care about immortality.

English
1
1
5
951
Lifespan
Lifespan@JoinLifespan·
If you want to live a long, healthy life, Lifespan Magazine is for you No hype, only evidence-based insights & actionable advice, so you can live your best possible life Because we only get one☝️ Coming April 2026 @joinlifespan
Lifespan tweet media
English
7
15
167
65.9K
Ronald A. Primas,MD,FACP,FACPM retweetou
David Sinclair
David Sinclair@davidasinclair·
P7C3 is an activator of an enzyme that makes NAD called NAMPT. Cool that it’s working in a 🐁 model of AD 👏
🔬 RicardoMontes@_MCRicardo_

Advanced Alzheimer’s Can Be Reversed With NAD+ Restoration, Study Shows in Mice Key Points: ▶️ Restoring brain NAD+ with a molecule that balances NAD+ metabolism, P7C3-A20, can reverse Alzheimer’s disease (AD)-related memory and learning deficits in mice. ▶️ In symptomatic AD mice, P7C3-A20 can reverse amyloid plaque accumulation, neuroinflammation, and young and mature neuronal cell death. ▶️ NAD+ balance dysregulation correlates with AD severity in mice and humans, and comparing NAD+’s effects on AD mice and humans’ proteins highlights reversal nodes. nad.com/news/advanced-… @CelestinoGutirr @drfherediaz @DrRPalmquist @HealthyFellow @LoriShemek @_atanas_

English
10
21
227
27.2K
Ronald A. Primas,MD,FACP,FACPM retweetou
Max Gulhane MD
Max Gulhane MD@MaxGulhaneMD·
The red/NIR spectrum is what has been stripped and removed from indoor LED lighting Unsurprising if the list of conditions highlighted in this review arise from a life lived under this refined, alien light
Brandon Luu, MD@BrandonLuuMD

Benefits of red/near-infrared light therapy (photobiomodulation) according to a new umbrella review of RCTs: - Fibromyalgia fatigue - Knee osteoarthritis - Cognitive impairment - Hair growth

English
1
4
47
2.4K
Ronald A. Primas,MD,FACP,FACPM
Ronald A. Primas,MD,FACP,FACPM@Primas·
@perplexity_ai Pretty weak actually. I have 15 years of data (which is not a lot for me as they are essentially annual labs) and it couldn't process because the data set was too large. SMH
English
0
0
1
196
Perplexity
Perplexity@perplexity_ai·
Perplexity Computer now connects to your health apps, wearable devices, lab results, and medical records. Build personalized tools and applications with your health data, or track everything in your health dashboard.
English
196
322
3.3K
1.5M
Ronald A. Primas,MD,FACP,FACPM retweetou
Life Biosciences
Life Biosciences@lifebiosciences·
#ICYMI, our CSO, Sharon Rosenzweig-Lipson, PhD, was featured in @Labiotech_eu discussing how our recent IND clearance allows us to advance our lead partial epigenetic reprogramming therapy into the clinic to address optic neuropathies. Read more: bit.ly/4lvWFHj
Life Biosciences tweet media
English
3
5
16
1.4K
Ronald A. Primas,MD,FACP,FACPM retweetou
Aubrey de Grey
Aubrey de Grey@aubreydegrey·
R2T is gathering pace!
The Alliance for Longevity Initiatives (A4LI)@theA4LI

The Alliance for Longevity Initiatives (A4LI) would like to applaud the passage of HB1734 and HB1735 in the New Hampshire House of Representatives, two groundbreaking pieces of legislation designed to expand patient access to cutting-edge medical treatments and accelerate the development of next-generation therapies. Together, these bills represent a major step toward making New Hampshire a national leader in biomedical innovation and patient access to promising therapies. The legislation builds on reforms A4LI advocated for in Montana, where policymakers previously enacted similar policies designed to expand access to experimental therapies while encouraging biomedical innovation. We look forward to keeping you all updated as both pieces of legislation now advance to the New Hampshire Senate for consideration.

English
0
9
29
3.3K
Ronald A. Primas,MD,FACP,FACPM
Ronald A. Primas,MD,FACP,FACPM@Primas·
Well done!!!
The Alliance for Longevity Initiatives (A4LI)@theA4LI

The Alliance for Longevity Initiatives (A4LI) would like to applaud the passage of HB1734 and HB1735 in the New Hampshire House of Representatives, two groundbreaking pieces of legislation designed to expand patient access to cutting-edge medical treatments and accelerate the development of next-generation therapies. Together, these bills represent a major step toward making New Hampshire a national leader in biomedical innovation and patient access to promising therapies. The legislation builds on reforms A4LI advocated for in Montana, where policymakers previously enacted similar policies designed to expand access to experimental therapies while encouraging biomedical innovation. We look forward to keeping you all updated as both pieces of legislation now advance to the New Hampshire Senate for consideration.

English
0
0
1
19
Ronald A. Primas,MD,FACP,FACPM retweetou
Agingdoc🩺Dr David Barzilai🔔MD PhD MS MBA DipABLM
Agingdoc🩺Dr David Barzilai🔔MD PhD MS MBA DipABLM@agingdoc1·
👉 “humans now spend the majority of their adult lives in a "healthy but declined" state, characterized by a significant "functional gap." 👉 We argue that extending Peakspan and developing strategies to restore function in post-peak individuals is the functional manifestation of rejuvenative biomedical progress and is essential for sustained economic growth in aging societies.”
Agingdoc🩺Dr David Barzilai🔔MD PhD MS MBA DipABLM@agingdoc1

Peakspan: Defining, Quantifying and Extending the Boundaries of Peak Productive Lifespan @biogerontology @KejunYing @DomiWilczok aginganddisease.org/EN/10.14336/AD…

English
2
7
20
1.7K
Ronald A. Primas,MD,FACP,FACPM retweetou
Jonathan Jarecki
Jonathan Jarecki@Jonathanjarecki·
Sunlight isn’t just vitamin D…it’s so much more. The sun, when UVA is present, provides so many other biochemical compounds including, but not limited to, nitric oxide. There are other compounds produced via sunlight exposure, including Pro-opiomelanocortin (POMC), a 241-amino acid polypeptide precursor which is cleaved into crucial peptide hormones, including ACTH, 𝛼-MSH, and β-endorphin. This will be for another post.
Jonathan Jarecki tweet mediaJonathan Jarecki tweet mediaJonathan Jarecki tweet mediaJonathan Jarecki tweet media
English
4
20
104
4.7K
Ronald A. Primas,MD,FACP,FACPM retweetou
Healthspan
Healthspan@healthspanmed·
The first human longevity trials are revealing something unexpected about rapamycin timing. It's not continuous mTOR suppression that drives healthspan benefits—it's the oscillation between suppression and recovery that appears to activate cellular maintenance pathways. We synthesized findings across animal models, dog trials, and emerging human studies to ask a simple question: how do you harness rapamycin's healthspan biology without disrupting normal cellular function? Our latest Research Review explores what the biology—and new human evidence—are starting to reveal. gethealthspan.com/research/artic…
English
4
36
182
14.1K

Descobrir

@Noahpinion @JoinLifespan @joinlifespan @perplexity_ai @davidasinclair @Labiotech_eu @statto @elonmusk